Sandra S. S.
- Country
- Germany
- Department
- Staedisches Klinikum Brandenburg
Research Overview
- Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy
- Efficacy and Safety of Glofitamab with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Untreated Large B-Cell Lymphoma
Data & Insights
Has run more than one trial at 8 of 87 partner sites.
Specializations
Lymphoma Research
This investigator specializes in the treatment of B-cell lymphomas, with particular expertise in both Large B-Cell Lymphoma and Mantle Cell Lymphoma.
- Advanced B-cell lymphoma therapeutics
- Novel combination treatment approaches
- Targeted immunotherapy strategies
The investigator focuses on evaluating innovative therapeutic combinations incorporating targeted agents and immunotherapies.
Therapeutic Innovation
Primary research interests include the development of novel treatment combinations using both established and emerging therapeutic agents in lymphoid malignancies.
- Antibody-based therapies
- Targeted molecular agents
- Chemotherapy optimization
The investigator explores treatment approaches combining rituximab-based regimens with newer therapeutic agents.
Clinical Outcomes
Research focus includes evaluation of treatment efficacy and survival outcomes in lymphoma patients.
- Progression-free survival assessment
- Treatment failure analysis
- Long-term outcome studies
The investigator evaluates therapeutic effectiveness through comprehensive clinical endpoints in lymphoma treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.